STOCK TITAN

[Form 4] Cipher Mining Inc. Warrant Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Atlas Venture funds have filed Amendment No. 1 to their Schedule 13D for ImageneBio, Inc. (formerly Ikena Oncology, Nasdaq: IKNA) to report dilution of their holdings after the 1-for-12 reverse stock split and completion of Ikena’s all-stock merger with Inmagene on 25 Jul 2025.

  • Collectively, the reporting entities now own 418,179 post-split common shares, equal to 3.6 % of the 11.6 million shares outstanding.
  • Breakdown: Fund X 241,800 shares (2.1 %), Fund XI 103,494 shares (0.9 %), Opportunity Fund I 72,885 shares (0.6 %).
  • All voting and dispositive powers are shared among the respective limited partnerships and their general partners; no sole voting power is reported.
  • The funds ceased to be 5 % beneficial owners on 25 Jul 2025; no purchases or sales occurred in the past 60 days.
  • Purpose: administrative update reflecting dilution from the merger and reverse split; Atlas Venture continues to hold the same absolute number of economic shares pre-transaction but a lower percentage.

Atlas Venture disclaims group status among the reporting persons. A joint filing agreement is included as Exhibit 99.1.

I fondi Atlas Venture hanno presentato l'Emendamento n. 1 al loro Schedule 13D per ImageneBio, Inc. (precedentemente Ikena Oncology, Nasdaq: IKNA) per segnalare la diluizione delle loro partecipazioni dopo il frazionamento azionario inverso 1-per-12 e il completamento della fusione interamente azionaria di Ikena con Inmagene il 25 luglio 2025.

  • Collettivamente, gli enti segnalanti possiedono ora 418.179 azioni ordinarie post-frazionamento, pari al 3,6% delle 11,6 milioni di azioni in circolazione.
  • Dettaglio: Fund X 241.800 azioni (2,1%), Fund XI 103.494 azioni (0,9%), Opportunity Fund I 72.885 azioni (0,6%).
  • Tutti i poteri di voto e dispositivi sono condivisi tra le rispettive società in accomandita semplice e i loro soci accomandatari; non è riportato alcun potere di voto esclusivo.
  • I fondi hanno cessato di essere beneficiari del 5% il 25 luglio 2025; non sono state effettuate compravendite negli ultimi 60 giorni.
  • Scopo: aggiornamento amministrativo che riflette la diluizione derivante dalla fusione e dal frazionamento azionario inverso; Atlas Venture mantiene lo stesso numero assoluto di azioni economiche pre-transazione ma con una percentuale inferiore.

Atlas Venture nega lo status di gruppo tra le persone segnalanti. Un accordo di deposito congiunto è incluso come Allegato 99.1.

Los fondos Atlas Venture han presentado la Enmienda No. 1 a su Schedule 13D para ImageneBio, Inc. (anteriormente Ikena Oncology, Nasdaq: IKNA) para informar la dilución de sus participaciones tras la división inversa de acciones 1 por 12 y la finalización de la fusión totalmente en acciones de Ikena con Inmagene el 25 de julio de 2025.

  • En conjunto, las entidades que informan ahora poseen 418,179 acciones ordinarias posteriores a la división, equivalentes al 3.6% de las 11.6 millones de acciones en circulación.
  • Desglose: Fund X 241,800 acciones (2.1%), Fund XI 103,494 acciones (0.9%), Opportunity Fund I 72,885 acciones (0.6%).
  • Todos los poderes de voto y disposición se comparten entre las sociedades limitadas respectivas y sus socios generales; no se reporta ningún poder de voto exclusivo.
  • Los fondos dejaron de ser propietarios beneficiarios del 5% el 25 de julio de 2025; no hubo compras ni ventas en los últimos 60 días.
  • Propósito: actualización administrativa que refleja la dilución por la fusión y la división inversa; Atlas Venture continúa manteniendo el mismo número absoluto de acciones económicas antes de la transacción pero con un porcentaje menor.

Atlas Venture niega el estatus de grupo entre las personas que informan. Un acuerdo de presentación conjunta está incluido como Anexo 99.1.

Atlas Venture 펀드들은 ImageneBio, Inc. (이전 Ikena Oncology, Nasdaq: IKNA)에 대한 Schedule 13D의 수정안 1호를 제출하여 2025년 7월 25일 1대 12 역분할 및 Ikena와 Inmagene 간 전액 주식 합병 완료 후 보유 지분 희석을 보고했습니다.

  • 보고 기관들은 현재 합산하여 418,179주의 역분할 후 보통주를 보유하고 있으며, 이는 총 1,160만 주 중 3.6%에 해당합니다.
  • 내역: Fund X 241,800주 (2.1%), Fund XI 103,494주 (0.9%), Opportunity Fund I 72,885주 (0.6%).
  • 모든 의결권 및 처분 권한은 각 유한책임조합과 일반 파트너 간에 공유되며, 단독 의결권은 보고되지 않았습니다.
  • 펀드들은 2025년 7월 25일부로 5% 이상 지분 보유자 지위를 상실했으며, 최근 60일간 매매 내역은 없습니다.
  • 목적: 합병 및 역분할에 따른 희석 반영을 위한 행정적 업데이트; Atlas Venture는 거래 전과 동일한 절대 수의 경제적 주식을 보유하나 비율은 감소했습니다.

Atlas Venture는 보고자들 간의 그룹 지위를 부인합니다. 공동 제출 계약서는 첨부문서 99.1에 포함되어 있습니다.

Les fonds Atlas Venture ont déposé l'Amendement n°1 à leur Schedule 13D pour ImageneBio, Inc. (anciennement Ikena Oncology, Nasdaq : IKNA) afin de signaler la dilution de leurs participations suite au regroupement d'actions inverse 1 pour 12 et à la finalisation de la fusion entièrement en actions d'Ikena avec Inmagene le 25 juillet 2025.

  • Collectivement, les entités déclarantes détiennent désormais 418 179 actions ordinaires post-regroupement, soit 3,6 % des 11,6 millions d'actions en circulation.
  • Répartition : Fund X 241 800 actions (2,1 %), Fund XI 103 494 actions (0,9 %), Opportunity Fund I 72 885 actions (0,6 %).
  • Tous les droits de vote et de disposition sont partagés entre les sociétés en commandite respectives et leurs associés commandités ; aucun pouvoir de vote exclusif n'est déclaré.
  • Les fonds ont cessé d'être des propriétaires bénéficiaires à 5 % le 25 juillet 2025 ; aucune transaction d'achat ou de vente n'a eu lieu au cours des 60 derniers jours.
  • Objet : mise à jour administrative reflétant la dilution due à la fusion et au regroupement inverse ; Atlas Venture conserve le même nombre absolu d'actions économiques avant la transaction, mais avec un pourcentage moindre.

Atlas Venture décline le statut de groupe parmi les personnes déclarantes. Un accord de dépôt conjoint est inclus en Annexe 99.1.

Die Atlas Venture Fonds haben Nachtrag Nr. 1 zu ihrem Schedule 13D für ImageneBio, Inc. (ehemals Ikena Oncology, Nasdaq: IKNA) eingereicht, um die Verwässerung ihrer Beteiligungen nach dem 1-zu-12 Reverse Stock Split und dem Abschluss der vollständigen Aktientauschfusion von Ikena mit Inmagene am 25. Juli 2025 zu melden.

  • Gemeinsam halten die meldenden Einheiten nun 418.179 Aktien nach dem Split, was 3,6% von 11,6 Millionen ausstehenden Aktien entspricht.
  • Aufschlüsselung: Fund X 241.800 Aktien (2,1%), Fund XI 103.494 Aktien (0,9%), Opportunity Fund I 72.885 Aktien (0,6%).
  • Alle Stimm- und Verfügungsrechte werden zwischen den jeweiligen Kommanditgesellschaften und deren Komplementären geteilt; keine alleinigen Stimmrechte gemeldet.
  • Die Fonds haben am 25. Juli 2025 den Status als 5%-Eigentümer verloren; in den letzten 60 Tagen gab es keine Käufe oder Verkäufe.
  • Zweck: administrative Aktualisierung, die die Verwässerung durch Fusion und Reverse Split widerspiegelt; Atlas Venture hält weiterhin dieselbe absolute Anzahl wirtschaftlicher Aktien vor der Transaktion, jedoch einen geringeren Prozentsatz.

Atlas Venture weist den Gruppenstatus unter den meldenden Personen zurück. Eine gemeinsame Einreichungsvereinbarung ist als Anlage 99.1 beigefügt.

Positive
  • No insider selling: Atlas Venture did not dispose of any shares, signalling continued support for ImageneBio.
  • Merger completion and reverse split finalized, providing corporate clarity after the Inmagene transaction.
Negative
  • Ownership dilution: Atlas Venture’s combined stake falls below 5 %, slightly reducing insider alignment.
  • Lower reporting threshold: Future 13D filings may cease unless ownership rises again, reducing visibility into a key holder’s changes.

Insights

TL;DR – Atlas Venture’s stake falls to 3.6 % due to merger-related dilution; no shares sold, impact on IKNA share supply already known.

The amendment is largely administrative. Atlas Venture’s absolute share count is unchanged, but the completed Inmagene merger and 1-for-12 reverse split expanded the denominator, cutting their ownership below the 5 % 13D threshold. The filing removes a potential overhang concern of insider selling, as none occurred. From a governance lens, the reduced concentration slightly broadens the float, but Atlas remains a meaningful holder. Market impact is likely minimal because the share count change was disclosed in the July 25 reverse-split announcement and already reflected in trading. Overall, neutral for valuation and liquidity.

I fondi Atlas Venture hanno presentato l'Emendamento n. 1 al loro Schedule 13D per ImageneBio, Inc. (precedentemente Ikena Oncology, Nasdaq: IKNA) per segnalare la diluizione delle loro partecipazioni dopo il frazionamento azionario inverso 1-per-12 e il completamento della fusione interamente azionaria di Ikena con Inmagene il 25 luglio 2025.

  • Collettivamente, gli enti segnalanti possiedono ora 418.179 azioni ordinarie post-frazionamento, pari al 3,6% delle 11,6 milioni di azioni in circolazione.
  • Dettaglio: Fund X 241.800 azioni (2,1%), Fund XI 103.494 azioni (0,9%), Opportunity Fund I 72.885 azioni (0,6%).
  • Tutti i poteri di voto e dispositivi sono condivisi tra le rispettive società in accomandita semplice e i loro soci accomandatari; non è riportato alcun potere di voto esclusivo.
  • I fondi hanno cessato di essere beneficiari del 5% il 25 luglio 2025; non sono state effettuate compravendite negli ultimi 60 giorni.
  • Scopo: aggiornamento amministrativo che riflette la diluizione derivante dalla fusione e dal frazionamento azionario inverso; Atlas Venture mantiene lo stesso numero assoluto di azioni economiche pre-transazione ma con una percentuale inferiore.

Atlas Venture nega lo status di gruppo tra le persone segnalanti. Un accordo di deposito congiunto è incluso come Allegato 99.1.

Los fondos Atlas Venture han presentado la Enmienda No. 1 a su Schedule 13D para ImageneBio, Inc. (anteriormente Ikena Oncology, Nasdaq: IKNA) para informar la dilución de sus participaciones tras la división inversa de acciones 1 por 12 y la finalización de la fusión totalmente en acciones de Ikena con Inmagene el 25 de julio de 2025.

  • En conjunto, las entidades que informan ahora poseen 418,179 acciones ordinarias posteriores a la división, equivalentes al 3.6% de las 11.6 millones de acciones en circulación.
  • Desglose: Fund X 241,800 acciones (2.1%), Fund XI 103,494 acciones (0.9%), Opportunity Fund I 72,885 acciones (0.6%).
  • Todos los poderes de voto y disposición se comparten entre las sociedades limitadas respectivas y sus socios generales; no se reporta ningún poder de voto exclusivo.
  • Los fondos dejaron de ser propietarios beneficiarios del 5% el 25 de julio de 2025; no hubo compras ni ventas en los últimos 60 días.
  • Propósito: actualización administrativa que refleja la dilución por la fusión y la división inversa; Atlas Venture continúa manteniendo el mismo número absoluto de acciones económicas antes de la transacción pero con un porcentaje menor.

Atlas Venture niega el estatus de grupo entre las personas que informan. Un acuerdo de presentación conjunta está incluido como Anexo 99.1.

Atlas Venture 펀드들은 ImageneBio, Inc. (이전 Ikena Oncology, Nasdaq: IKNA)에 대한 Schedule 13D의 수정안 1호를 제출하여 2025년 7월 25일 1대 12 역분할 및 Ikena와 Inmagene 간 전액 주식 합병 완료 후 보유 지분 희석을 보고했습니다.

  • 보고 기관들은 현재 합산하여 418,179주의 역분할 후 보통주를 보유하고 있으며, 이는 총 1,160만 주 중 3.6%에 해당합니다.
  • 내역: Fund X 241,800주 (2.1%), Fund XI 103,494주 (0.9%), Opportunity Fund I 72,885주 (0.6%).
  • 모든 의결권 및 처분 권한은 각 유한책임조합과 일반 파트너 간에 공유되며, 단독 의결권은 보고되지 않았습니다.
  • 펀드들은 2025년 7월 25일부로 5% 이상 지분 보유자 지위를 상실했으며, 최근 60일간 매매 내역은 없습니다.
  • 목적: 합병 및 역분할에 따른 희석 반영을 위한 행정적 업데이트; Atlas Venture는 거래 전과 동일한 절대 수의 경제적 주식을 보유하나 비율은 감소했습니다.

Atlas Venture는 보고자들 간의 그룹 지위를 부인합니다. 공동 제출 계약서는 첨부문서 99.1에 포함되어 있습니다.

Les fonds Atlas Venture ont déposé l'Amendement n°1 à leur Schedule 13D pour ImageneBio, Inc. (anciennement Ikena Oncology, Nasdaq : IKNA) afin de signaler la dilution de leurs participations suite au regroupement d'actions inverse 1 pour 12 et à la finalisation de la fusion entièrement en actions d'Ikena avec Inmagene le 25 juillet 2025.

  • Collectivement, les entités déclarantes détiennent désormais 418 179 actions ordinaires post-regroupement, soit 3,6 % des 11,6 millions d'actions en circulation.
  • Répartition : Fund X 241 800 actions (2,1 %), Fund XI 103 494 actions (0,9 %), Opportunity Fund I 72 885 actions (0,6 %).
  • Tous les droits de vote et de disposition sont partagés entre les sociétés en commandite respectives et leurs associés commandités ; aucun pouvoir de vote exclusif n'est déclaré.
  • Les fonds ont cessé d'être des propriétaires bénéficiaires à 5 % le 25 juillet 2025 ; aucune transaction d'achat ou de vente n'a eu lieu au cours des 60 derniers jours.
  • Objet : mise à jour administrative reflétant la dilution due à la fusion et au regroupement inverse ; Atlas Venture conserve le même nombre absolu d'actions économiques avant la transaction, mais avec un pourcentage moindre.

Atlas Venture décline le statut de groupe parmi les personnes déclarantes. Un accord de dépôt conjoint est inclus en Annexe 99.1.

Die Atlas Venture Fonds haben Nachtrag Nr. 1 zu ihrem Schedule 13D für ImageneBio, Inc. (ehemals Ikena Oncology, Nasdaq: IKNA) eingereicht, um die Verwässerung ihrer Beteiligungen nach dem 1-zu-12 Reverse Stock Split und dem Abschluss der vollständigen Aktientauschfusion von Ikena mit Inmagene am 25. Juli 2025 zu melden.

  • Gemeinsam halten die meldenden Einheiten nun 418.179 Aktien nach dem Split, was 3,6% von 11,6 Millionen ausstehenden Aktien entspricht.
  • Aufschlüsselung: Fund X 241.800 Aktien (2,1%), Fund XI 103.494 Aktien (0,9%), Opportunity Fund I 72.885 Aktien (0,6%).
  • Alle Stimm- und Verfügungsrechte werden zwischen den jeweiligen Kommanditgesellschaften und deren Komplementären geteilt; keine alleinigen Stimmrechte gemeldet.
  • Die Fonds haben am 25. Juli 2025 den Status als 5%-Eigentümer verloren; in den letzten 60 Tagen gab es keine Käufe oder Verkäufe.
  • Zweck: administrative Aktualisierung, die die Verwässerung durch Fusion und Reverse Split widerspiegelt; Atlas Venture hält weiterhin dieselbe absolute Anzahl wirtschaftlicher Aktien vor der Transaktion, jedoch einen geringeren Prozentsatz.

Atlas Venture weist den Gruppenstatus unter den meldenden Personen zurück. Eine gemeinsame Einreichungsvereinbarung ist als Anlage 99.1 beigefügt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
V3 Holding Ltd

(Last) (First) (Middle)
4TH FL HARBOUR PL 103 S CHURCH ST, 10240

(Street)
GRAND CAYMAN E9 KY1-1002

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cipher Mining Inc. [ CIFR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/25/2025 S 500,000 D $6.45(1) 91,878,292 I See Footnote(3)(4)
Common Stock 07/28/2025 S 500,000 D $6.19(2) 91,378,292 I See Footnote(3)(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
V3 Holding Ltd

(Last) (First) (Middle)
4TH FL HARBOUR PL 103 S CHURCH ST, 10240

(Street)
GRAND CAYMAN E9 KY1-1002

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Bitfury Top HoldCo B.V.

(Last) (First) (Middle)
STRAWINSKYLAAN 3051

(Street)
AMSTERDAM P7 1077 ZX

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Bitfury Holding B.V.

(Last) (First) (Middle)
STRAWINSKYLAAN 3051

(Street)
AMSTERDAM P7 1077 ZX

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Vavilovs Valerijs

(Last) (First) (Middle)
2102 CHEDDAR CHEESE TOWER, PO BOX 712650

(Street)
DUBAI C0

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Bitfury Group Ltd

(Last) (First) (Middle)
FIELDFISHER RIVERBANK HOUSE, 2 SWAN LANE

(Street)
LONDON X0 EC4R 3TT

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 represents a weighted average sales price of $6.4542. These shares were sold in multiple transactions at prices ranging from $6.3128 to $6.5669, inclusive. The reporting person undertakes to provide to Cipher Mining Inc., any security holder of Cipher Mining Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 2 of this Form 4.
2. The price reported in Column 4 represents a weighted average sales price of $6.1874. These shares were sold in multiple transactions at prices ranging from $6.08 to $6.63, inclusive.
3. Bitfury Holding B.V. is the record holder of 4,821,560 shares of Common Stock. Bitfury Top HoldCo B.V. ("Bitfury Top HoldCo") is the record holder of 43,911,544 shares of Common Stock and is the sole owner of Bitfury Holding B.V. As a result, Bitfury Top HoldCo may be deemed to share beneficial ownership of the shares of Common Stock held by Bitfury Holding B.V. V3 Holding Limited ("V3") is the direct holder of 42,645,188 shares of Common Stock. Valerijs Vavilovs is the sole owner of V3, which is the majority owner of Bitfury Group Limited ("BGL"). BGL is the sole owner of Bitfury Top HoldCo. [Continued]
4. [Cont.] As a result of the foregoing relationships, each of Mr. Vavilovs, V3 and BGL may be deemed to share beneficial ownership of the Common Stock beneficially owned by Bitfury Top HoldCo, and Mr. Vavilovs may be deemed to have beneficial ownership of the Common Stock owned by V3. Each of Mr. Vavilovs, V3, Bitfury Top HoldCo, BGL and Bitfury Holding B.V. disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
Stijn Ehren, Managing Director of Bitfury Top HoldCo B.V., By: /s/ Stijn Ehren 07/29/2025
Stijn Ehren, Managing Director of Bitfury Holding B.V., By: /s/ Stijn Ehren 07/29/2025
Valerijs Vavilovs, Director of Bitfury Group Limited, By: /s/ Valerijs Vavilovs 07/29/2025
Valerijs Vavilovs, Director of V3 Holding Limited, By: /s/ Valerijs Vavilovs 07/29/2025
Valerijs Vavilovs, By: /s/ Valerijs Vavilovs 07/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Atlas Venture file an amended Schedule 13D for IKNA?

To report that its percentage ownership fell to 3.6 % after IKNA’s merger with Inmagene and a 1-for-12 reverse split on 25 Jul 2025.

How many IKNA shares does Atlas Venture now own?

Collectively 418,179 shares: Fund X 241,800; Fund XI 103,494; Opportunity Fund I 72,885.

Did Atlas Venture sell any IKNA shares?

No. The filing states no purchases or sales occurred in the past 60 days; dilution alone lowered the percentage.

What is IKNA’s new share count after the merger?

The filing references approximately 11.6 million common shares outstanding as of 25 Jul 2025.

Does Atlas Venture still have voting control over its IKNA shares?

Yes. Each fund and its general partners retain shared voting and dispositive power over their respective shares.
Cipher Mining Inc.

NASDAQ:CIFRW

CIFRW Rankings

CIFRW Latest News

CIFRW Latest SEC Filings

CIFRW Stock Data

370.86M
Capital Markets
Finance Services
Link
United States
NEW YORK